SG11202000896VA - Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders - Google Patents

Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders

Info

Publication number
SG11202000896VA
SG11202000896VA SG11202000896VA SG11202000896VA SG11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA
Authority
SG
Singapore
Prior art keywords
disorders
treating
related diseases
hepatitis virus
preventing hepatitis
Prior art date
Application number
SG11202000896VA
Other languages
English (en)
Inventor
Yifan Zhai
Xiaoyong Zhang
Jinlin Hou
Dajun Yang
Original Assignee
Jiangsu Ascentage Biomed Dev Inc
Healthquest Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Ascentage Biomed Dev Inc, Healthquest Pharma Inc filed Critical Jiangsu Ascentage Biomed Dev Inc
Publication of SG11202000896VA publication Critical patent/SG11202000896VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202000896VA 2017-11-24 2018-11-20 Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders SG11202000896VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711193388.1A CN107987083A (zh) 2017-11-24 2017-11-24 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
PCT/CN2018/116289 WO2019101047A1 (zh) 2017-11-24 2018-11-20 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物

Publications (1)

Publication Number Publication Date
SG11202000896VA true SG11202000896VA (en) 2020-02-27

Family

ID=62033007

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000896VA SG11202000896VA (en) 2017-11-24 2018-11-20 Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders

Country Status (11)

Country Link
US (2) US11298339B2 (de)
EP (1) EP3715349A4 (de)
JP (1) JP2021504294A (de)
KR (1) KR102348735B1 (de)
CN (2) CN107987083A (de)
AU (1) AU2018372851B2 (de)
CA (1) CA3072733C (de)
RU (1) RU2749730C1 (de)
SG (1) SG11202000896VA (de)
TW (1) TWI732156B (de)
WO (1) WO2019101047A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
EP3829639A4 (de) * 2018-07-31 2022-06-29 Ascentage Pharma (Suzhou) Co., Ltd. Verfahren zur behandlung von krebs mit einer kombination aus iap-inhibitor und modulator eines immun-checkpoint-moleküls
US20220047606A1 (en) * 2019-11-19 2022-02-17 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with iap inhibitor
US20230078120A1 (en) * 2020-05-04 2023-03-16 Ascentage Pharma (Suzhou) Co.,Ltd. Methods for Treating Coronavirus Infections
US20230257384A1 (en) * 2020-07-16 2023-08-17 Ascentage Pharma (Suzhou) Co., Ltd. The crystalline forms or amorphous forms of bisdiazabicyclic compounds or salts thereof
CN112472808A (zh) * 2020-12-04 2021-03-12 南方医科大学南方医院 凋亡抑制蛋白作为肝纤维化或肝硬化治疗药物靶点的应用
CN116963732A (zh) * 2021-02-23 2023-10-27 苏州亚盛药业有限公司 药物组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4674231B2 (ja) 2004-03-01 2011-04-20 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 2量体小分子アポトーシス増強剤
CN101484151B (zh) 2006-05-05 2012-11-21 密执安州立大学董事会 二价smac模拟物及其应用
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8030307B2 (en) * 2007-11-29 2011-10-04 Enanta Pharmaceuticals, Inc. Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
NZ591973A (en) * 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
EP2491041B1 (de) 2009-10-23 2017-08-09 The Regents of the University of Michigan Bivalente und bizyklische diazo-smac-mimetika und ihre anwendungen
CA2882496C (en) * 2012-08-23 2020-07-14 The Regents Of The University Of Michigan Bivalent inhibitors of iap proteins and therapeutic methods using the same
AU2014301958B2 (en) 2013-06-25 2017-11-16 The Walter And Eliza Hall Institute Of Medical Research Method of treating intracellular infection
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US20170037004A1 (en) 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物

Also Published As

Publication number Publication date
KR102348735B1 (ko) 2022-01-06
KR20200043995A (ko) 2020-04-28
US11298339B2 (en) 2022-04-12
CN109467566A (zh) 2019-03-15
EP3715349A4 (de) 2021-08-18
CA3072733C (en) 2023-02-21
CN107987083A (zh) 2018-05-04
EP3715349A1 (de) 2020-09-30
CA3072733A1 (en) 2019-05-31
AU2018372851B2 (en) 2021-09-16
JP2021504294A (ja) 2021-02-15
TWI732156B (zh) 2021-07-01
TW202017933A (zh) 2020-05-16
WO2019101047A1 (zh) 2019-05-31
CN109467566B (zh) 2020-12-04
AU2018372851A1 (en) 2020-02-20
US20210290594A1 (en) 2021-09-23
RU2749730C1 (ru) 2021-06-16
US20220296571A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
SG11202000896VA (en) Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
IL264156A (en) Compounds, preparations and methods for treating the disease
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
EP3634442A4 (de) Verfahren zur behandlung und prävention von erkrankungen
ZA201705633B (en) A new quinoline derivative for use in the treatment and prevention of viral infections
IL275482A (en) Asketamine for the treatment of depression
IL260352B (en) Methods and preparations for the treatment of neurological disease
IL259861A (en) Methods and preparations for the treatment of disorders related to seizures
LT3261642T (lt) Chinolino dariniai, skirti naudoti virusinės infekcijos gydymui arba prevencijai
IL283948A (en) Methods for treating depression
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
EP3634431A4 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von hepatitis b
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
ZA201907975B (en) Agent for preventing or treating tauopathy
IL275573A (en) Methods and preparations for the treatment of hypercytokinemia and severe influenza or for their prevention
HK1255835A1 (zh) 用於治療乙型肝炎的治療組合物及方法
HK1255695A1 (zh) 用於治療眼瞼下垂的組合物和方法
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
GB201617715D0 (en) Methods for the treatment and prevention of ebola
HK1252670A1 (zh) 用於治療和/或預防與肝炎病毒相關的疾病或病症的雙二氮雜雙環化合物
EP3648768C0 (de) Imeglimin zur prävention und/oder behandlung von leberzellkarzinomen
GB201617591D0 (en) Methods for the treatment and prevention of ebola